☆ 4.8 Editorial Material

NAM 2017 Report: A National Plan to Eliminate Hepatitis B and C in the United States by 2030 and the AASLD's Response

HEPATOLOGY (2017)

Get Full Text
Add to Collection

Journal

HEPATOLOGY
Volume 66, Issue 4, Pages 1020-1022

Publisher

WILEY
DOI: 10.1002/hep.29361

Keywords

-

Categories

Gastroenterology & Hepatology

Funding

  1. Gilead
  2. AbbVie
  3. Janssen
  4. Bristol-Myers Squibb
  5. Merck

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.